# FDC share price today (FDC Ltd, NSE: FDC)

> FDC share price today: ₹388.60 at the NSE close on 3 November 2026, down 15.6% in a year. FDC (NSE: FDC) is worth ₹6,327 crore, trades at a P/E of 19.3 and has closed between ₹321.10 and ₹433.80 over the past 52 weeks. > FDC Ltd's earnings have grown faster than its share price. Earnings per share grew +5.5% in a year while the price moved −15.6%. FDC · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/fdc-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from the last 12 quarters
- Price: ₹388.60 (−15.6% in a year)
- P/E: 19.3× (lower than 68% of the last 11 years)
- Revenue (Sep 2026): ₹572 Cr (+20.9% on a year ago)
- Profit (Sep 2026): ₹49.0 Cr (+75.0% on a year ago)
- Operating margin: 11.0% (+4.0 points on a year ago)
- ROCE: 15%, FY26
- ROIC: 11.9%, against a 12.0% cost of capital: −0.1 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the FDC share price today? FDC Ltd's share price was ₹388.60 at the close on 3 November 2026. It has been falling for 10 weeks. That is 2.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹321 and ₹434, and at that close it sat 60% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row. Over the last 11 years the share price moved +109% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at FDC this quarter? 2. Indian funds and insurers (DIIs) raised their stake for 3 quarters in a row From 6.3% to 6.6% of the company by the September 2026 quarter. 3. Started beating the market again after 13 weeks behind it

## What are FDC's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), FDC reported revenue of ₹572 crore, up 20.9% from ₹473 crore a year earlier, and a profit of ₹49.0 crore, up 75.0% from ₹28.0 crore. ### FDC results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹572 crore | ₹473 crore | +20.9% |
| Profit | ₹49.0 crore | ₹28.0 crore | +75.0% |
| Earnings per share | ₹3.01 | ₹1.74 | +73.0% |
| Operating margin | 11.0% | 7.0% | +4.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 16 November 2023, about July to September 2023; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the FDC share price history? FDC closed at ₹388.60 on 3 November 2026, down 15.6% from ₹460.65 a year earlier (31 October 2025) and up 19.1% over five years. Its highest weekly close since March 2016 was ₹597.25 on 13 September 2024. ### FDC share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹338.70 | +14.7% |
| 1 month ago · 1 Oct 2026 | ₹335.90 | +15.7% |
| 6 months ago · 30 Apr 2026 | ₹364.45 | +6.6% |
| 1 year ago · 31 Oct 2025 | ₹460.65 | −15.6% |
| 3 years ago · 3 Nov 2023 | ₹362.35 | +7.2% |
| 5 years ago · 4 Nov 2021 | ₹326.30 | +19.1% |
| 10 years ago · 4 Nov 2016 | ₹215.30 | +80.5% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹185.60 | +109.4% |
| Highest weekly close since March 2016 · 13 Sep 2024 | ₹597.25 | −34.9% |
| Lowest weekly close since March 2016 · 15 Feb 2019 | ₹151.85 | +155.9% |
| 52-week high (weekly close) · 3 Jul 2026 | ₹433.80 | −10.4% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹321.10 | +21.0% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (560 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on FDC? 3 Nov 2026: FDC closed at ₹388.60, up 14.7% on the week and up 15.7% on the month. Results for July to September 2026: Revenue up 20.9% and profit up 75.0% on a year earlier. ### Earlier

- 11 Feb 2026: ex-date for an interim dividend of ₹5 a share. - 16 Nov 2023: FDC held its results call for July to September 2023. ## What dividend does FDC pay? FDC paid ₹5 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 1.29% at the ₹388.60 close on 3 November 2026. The last was an interim dividend of ₹5 a share, ex-date 11 February 2026. ### FDC dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 11 Feb 2026 | ₹5 | Interim |
| 22 Nov 2024 | ₹5 | Interim |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 2 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. FDC Ltd paid out 29% of its profit as dividends in FY26, and it paid a dividend in 7 of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did FDC management say on the latest results call? On the call for July to September 2023, held on 16 November 2023, FDC's management spoke about the quarter; the main points are below. Source: [the call transcript](https://files.tijorifinance.com/insight/india/3862/Conference Call/CC-Sep23.pdf). (From the call for July to September 2023, 16 November 2023. The July to September 2026 results are out since, so this part may be out of date until we update it.)

## Which stock lists is FDC on? FDC is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 6204.752785145889](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is FDC profitable? FDC Ltd earned ₹49.0 Cr of net profit in the Sep 2026 quarter, +75.0% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹281 Cr. Over 10 years profit has grown 5.2% a year on average. That is 8.6% of the quarter's revenue. The same quarter a year earlier earned ₹28.0 Cr. Why profit moved: revenue changed +20.9% on a year earlier and the margin moved +4.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +56.0% and revenue +10.8%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does FDC make, and is it growing? FDC Ltd reported ₹572 Cr of revenue in the Sep 2026 quarter, +20.9% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 10 years it has grown 8.1% a year on average. The last full year, FY26, came in at ₹2,171 Cr. The last four reported quarters add to ₹2,290 Cr. FY26 revenue was ₹2,171 Cr, +3.0% on the year before. Recent pace: the last four quarters grew +10.8% on average, against 8.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +10.3%, against +5.1% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +38.7%, against −0.6% a year (accelerating). ## How much of every ₹100 of sales does FDC keep? FDC Ltd's operating margin was 11.0% in the Sep 2026 quarter, 4.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 14.0% and 25.0%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed +4.1 percentage points on the year while gross margin changed −1.8 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is FDC's profit turning into cash? Over the last 3 years, 87% of FDC Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹200 Cr of operating cash against ₹281 Cr of profit. After ₹165 Cr of spending on assets, ₹35.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 87% of profit came in as cash: the cash cycle got 50 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 2.3× depreciation over three years. The next section checks what that spending is building. ## Where does FDC's cash go? FDC Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 102 days in FY26, down from 152 days in FY21. It spent ₹351 Cr on assets over the last 3 years. Customers take 26 days to pay, and stock sits for 182 days on average. At FY26 sales of ₹2,171 Cr, each day of that cycle ties up about ₹5.9 Cr, so roughly ₹607 Cr is tied up in the business at any time. FY26: customers took 26 days to pay and stock sat for 182 days, about 6.0 months of sales sitting as stock, for a full cycle of 102 days, shorter than FY21's 152. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 182 days. Customers pay about 26 days after that. Suppliers are paid at 106 days. Together that makes the 102-day cycle. Spending on assets: ₹351 Cr over the last 3 years, against ₹153 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹96.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is FDC's P/E ratio, and how does it compare with its own history? FDC Ltd's P/E is 19.3×, near the low end of its own history: it has been lower only 32% of the time. Its usual P/E (the middle reading) is 22.6×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹19.24. Why the multiple is where it is: over the past year earnings per share moved +5.5% while the price moved −15.6%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +3.6% a year; about +1.9% a year came from earnings growth and about +1.7 percentage points from the multiple (the market paying more); over 10 years the price moved +6.1% a year; about +8.3% a year came from earnings growth and about −2.2 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the FDC business getting better or worse? FDC Ltd's business is turning around. Profit growth has swung from −21.2% at its low to +38.7%, improving for 3 quarters in a row, with ROCE rising at 16.0%. This is based on 12 quarters of 4 measures. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. ## How much does FDC earn on its capital? FDC Ltd earned a ROCE of 15% in FY26. That is up from a low of 13% in FY23. Its return on capital used (ROIC) is 0.1 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 12.9% net margin and 0.74× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 12.9% net margin × 0.74× asset turnover × 1.17× leverage (assets divided by equity) ≈ 11.2% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 11.9% − 12.0% = −0.1 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does FDC have too much debt? FDC Ltd has total debt of ₹13.0 Cr against shareholder equity of ₹2,669 Cr as of Sep 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.02 in FY22 to 0.01 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the FDC shareholding pattern? Foreign institutions cut their stake in FDC Ltd by 1.1 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 1.6% of the company. Domestic institutions moved +0.6 points over the same period, to 6.6%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −1.1 points over 8 quarters, to 1.6%; Domestic institutions: +0.6 points over 8 quarters, to 6.6%; Promoters: +0.0 points over 8 quarters, to 69.7%. Why the owners changed: foreign institutions drove it (−1.1 points), with the other side taken by domestic institutions (+0.6 points). They reduced their stake. ## How far is FDC from balance-sheet trouble? For FDC Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does FDC rank in its industry? 62.8 out of 100, rank 11 of 44 in Pharma - Formulators, with 85% of the evidence available. FDC Ltd scores 62.8 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 11. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 25.3 + 12.4 + 14.9 + 10.2 = 62.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is FDC compared with? FDC ranks 11 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 62.8 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. FDC Ltd this page FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 10.3% · Profit 38.7% · Operating margin change 4 points · 100% evidence Capital efficiency 12.4/25 · ROCE 15.4% · Operating margin 11% · 100% evidence Valuation 14.9/20 · P/E 18.7× · PEG 1.25 · 100% evidence Relative strength 10.2/20 · Lead over its industry n/a · Lead over NIFTY 500 4.9% · 1 year -18.2% · 25% evidence · 0 of 12 weeks ahead Exact sum: 25.3 + 12.4 + 14.9 + 10.2 = 62.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative
16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative
17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to FDC in size? FDC is the 28th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Strides Pharma Science, Suven Life Sciences and Bliss GVS Pharma. Just below it: RPG Life Sciences, Gufic BioSciences and Kwality Pharmaceuticals. ### Pharma - Formulators companies close in size

1. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) ₹9,851 crore
2. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) ₹7,314 crore
3. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) ₹6,888 crore
4. FDC Ltd ₹6,138 crore
5. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) ₹4,260 crore
6. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) ₹4,147 crore
7. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) ₹3,606 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Shrem InvIT](https://www.sectoralpha.in/stocks/shrem-invit) ₹6,176 crore · Infrastructure Investment Trusts
2. [Waterways Leisure Tourism Limited](https://www.sectoralpha.in/stocks/waterways-leisure-tourism-limited) ₹6,166 crore
3. FDC Ltd ₹6,138 crore
4. [Le Travenues Technology Ltd](https://www.sectoralpha.in/stocks/le-travenues-technology-ltd) ₹6,138 crore · E-Commerce - Platform - Travel
5. [Equitas Small Finance Bank Ltd](https://www.sectoralpha.in/stocks/equitas-small-finance-bank-ltd) ₹6,131 crore · Banks - Small Finance

## What else do people ask about FDC? ### What is FDC's share price today? FDC Ltd's share price is ₹388.60, −15.6% over the past year. The whole company is worth ₹6,327 Cr on the market. In the last 52 weeks it traded between ₹321 to ₹434; today it is 60% of the way up from the low, 2.9% above its 200-day average (as of 3 November 2026). ### What were FDC's latest quarterly results? FDC Ltd reported revenue of ₹572 Cr and net profit of ₹49.0 Cr for the Sep 2026 quarter. Revenue rose 20.9% and profit rose 75.0% compared with a year earlier. Earnings per share were ₹3.01. The operating margin was 11.0%, 4.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is FDC's market cap? FDC Ltd's market capitalisation is ₹6,327 Cr at a share price of ₹388.60. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is FDC performing? FDC Ltd's share price has been falling for 10 weeks. In its latest quarter, revenue rose 20.9% and profit rose 75.0% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 1 week running (as of 3 November 2026). ### Will FDC's share price go up? This page does not forecast FDC Ltd's share price. What it shows instead: the share price is ₹388.60, and it has been falling for 10 weeks. Its P/E of 19.3× is higher than 32% of its own last 11 years (as of 3 November 2026). ### Who owns FDC? Promoters own 69.7% of FDC Ltd, foreign institutions 1.6%, domestic institutions 6.6% and the public 22.2% (latest quarter). The biggest change over the last two years: Foreign institutions cut their stake by 1.1 percentage points over 8 quarters (as of 3 November 2026). ### Does FDC have too much debt? No, FDC Ltd has little debt: its debt is 0.01× its equity, and its operating profit is 69 times its interest bill. FY26 borrowings were ₹15.0 Cr against equity of ₹2,485 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is FDC in its business cycle? FDC Ltd's FY26 operating margin was 16.0%, against a 13-year range of 14.0% to 25.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 11.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the FDC story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is FDC a stock worth studying right now? What the numbers show: FDC Ltd's earnings have grown faster than its share price. Earnings per share grew +5.5% in a year while the price moved −15.6%. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.